Form 4: Shattuck Labs Director Mona Ashiya Receives Stock Options

Director Mona Ashiya was granted 81,000 stock options in Shattuck Labs, Inc. with an exercise price of $5.95.

Summary

• Director Mona Ashiya received a grant of 81,000 stock options for Shattuck Labs, Inc. common stock.
• The options have an exercise price of $5.95 per share.
• The grant date is May 29, 2026, with an expiration date of May 29, 2036.
• The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of stockholders.
• The reporting person is contractually obligated to transfer the economic benefit of these options to OrbiMed Advisors LLC and related entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The reporting person does not retain the economic benefit of the options, as they are transferred to OrbiMed entities.

Risks

• Vesting is subject to the reporting person's continued service to the issuer.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the issuer's next annual meeting of stockholders.

Management Comments

• The grant is subject to the Reporting Person's continued service to the Issuer.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance, though the pass-through arrangement to an investment firm is specific to institutional venture capital representation.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard director compensation packages for mid-cap biotechnology firms.
• The pass-through arrangement to OrbiMed is a common structure for venture capital-backed companies where the director represents the institutional investor.

Corporate Governance

Related Party Transactions

• The reporting person is obligated to transfer the economic benefit of the options to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of options on the earlier of May 29, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Shattuck Labs, STTK, Form 4, Director Compensation, Stock Options, OrbiMed